AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38320207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 38320238 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Number of subjects: 64
Study 38320238 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see
Number of subjects: 64
Study 38320240 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfascial injection of 10 mL of 10% dextrose water
Number of subjects: 35
Study 38320240 — intervention group
Group type: COMPARATOR
Intervention: Sham injection of 0.5 mL of 10% dextrose water
Number of subjects: 35
Study 38320248 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation
Number of subjects: 19
Study 38320248 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 19
Study 38320431 — intervention group
Group type: EXPERIMENTAL
Intervention: Peposertib 200 mg b.i.d. plus avelumab
Number of subjects: 44
Study 38320431 — intervention group
Group type: EXPERIMENTAL
Intervention: Peposertib 250 mg q.d. plus avelumab and radiotherapy
Number of subjects: 44
Study 38320431 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicity (DLT)
Number of subjects: 44
Study 38320431 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended phase II dose (RP2D) and maximum tolerated dose (MTD)
Number of subjects: 44
Study 38320431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of peposertib
Number of subjects: 44
Study 38320464 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled glycemia (glucose levels ≥175 mg/dL)
Number of subjects: 97
Study 38320464 — intervention group
Group type: COMPARATOR
Intervention: Controlled glycemia (glucose levels <175 mg/dL)
Number of subjects: 97
Study 38320464 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled glycemia
Number of subjects: 97
Study 38320464 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fasting glucose and HbA1C levels
Number of subjects: 97
Study 38320464 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with T2DM
Number of subjects: 97
Study 38320487 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized digital health intervention
Number of subjects: 0
Study 38320487 — intervention group
Group type: COMPARATOR
Intervention: Unoptimized digital health intervention
Number of subjects: 0
Study 38320486 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P/Gem-mFOLFOX
Number of subjects: 157
Study 38320486 — intervention group
Group type: COMPARATOR
Intervention: nab-P/Gem
Number of subjects: 157
Study 38320488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose 9vHPV vaccine (0 and 6 months)
Number of subjects: 438
Study 38320488 — intervention group
Group type: COMPARATOR
Intervention: Three-dose 9vHPV vaccine (0, 2, and 6 months)
Number of subjects: 438
Study 38320488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose 9vHPV vaccine
Number of subjects: 438
Study 38320488 — intervention group
Group type: COMPARATOR
Intervention: Three-dose 9vHPV vaccine
Number of subjects: 438
Study 38320489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4017
Study 38320489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4017
Study 38320499 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and LISA
Number of subjects: 180
Study 38320499 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and CPAP
Number of subjects: 180
Study 38320498 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-APOC3 10 mg
Number of subjects: 112
Study 38320498 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-APOC3 25 mg
Number of subjects: 112
Study 38320498 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-APOC3 50 mg
Number of subjects: 112
Study 38320498 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-APOC3 100 mg
Number of subjects: 112
Study 38320498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 38320500 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of dapagliflozin
Number of subjects: 245
Study 38320500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of saxagliptin
Number of subjects: 245
Study 38320500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 38320500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 245
Study 38320500 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 245
Study 38320501 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide alone
Number of subjects: 1068
Study 38320501 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (enzalutamide plus leuprolide)
Number of subjects: 1068
Study 38320501 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (enzalutamide)
Number of subjects: 1068
Study 38320511 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 352
Study 38320511 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 352
Study 38320511 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 352
Study 38320511 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 352
Study 38320513 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-208 5 mg twice daily with glucocorticoid/mineralocorticoid replacement
Number of subjects: 92
Study 38320513 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-208 5 mg twice daily
Number of subjects: 92
Study 38320513 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 92
Study 38320524 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin 0.5 μg/kg intravenously three times per week for 6 weeks
Number of subjects: 178
Study 38320524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 38320524 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin
Number of subjects: 178
Study 38320525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11007
Study 38320525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11007
Study 38320526 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAH (peanut allergen powder-dnfp)
Number of subjects: 146
Study 38320526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 38320526 — intervention group
Group type: EXPERIMENTAL
Intervention: PTAH
Number of subjects: 146
Study 38320527 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 38320527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat
Number of subjects: 160
Study 38320723 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote interactive telemedicine session and online genetic education
Number of subjects: 601
Study 38320723 — intervention group
Group type: COMPARATOR
Intervention: Online genetic education only
Number of subjects: 601
Study 38320840 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genomic sequencing (rGS)
Number of subjects: 250
Study 38320840 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about genomic medicine provided to neonatal providers
Number of subjects: 250
Study 38320840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interpretive reports created by the study team
Number of subjects: 250
Study 38320840 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of families for 12 months
Number of subjects: 250
Study 38321023 — intervention group
Group type: EXPERIMENTAL
Intervention: agenT-797 (donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy)
Number of subjects: 21
Study 38321085 — intervention group
Group type: EXPERIMENTAL
Intervention: IMU-based gait analysis during the 2-min walk test (2mWT)
Number of subjects: 26
Study 38321153 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application-based rehabilitation for chronic respiratory disease (n=41)
Number of subjects: 93
Study 38321153 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application-based rehabilitation for cardiovascular disease (n=52)
Number of subjects: 93
Study 38321218 — intervention group
Group type: EXPERIMENTAL
Intervention: OMO-103 (6.48 mg/kg, DL5)
Number of subjects: 22
Study 38321218 — intervention group
Group type: EXPERIMENTAL
Intervention: OMO-103 (DL5)
Number of subjects: 22
Study 38321218 — intervention group
Group type: EXPERIMENTAL
Intervention: OMO-103
Number of subjects: 22
Study 38321220 — intervention group
Group type: EXPERIMENTAL
Intervention: UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL
Number of subjects: 0
Study 38321220 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38321223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with systemic treatment
Number of subjects: 174
Study 38321223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) alone
Number of subjects: 174
Study 38321223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) as 2nd or further treatment-line
Number of subjects: 174
Study 38321223 — intervention group
Group type: EXPERIMENTAL
Intervention: Partition model dosimetry
Number of subjects: 174
Study 38321223 — intervention group
Group type: EXPERIMENTAL
Intervention: No extrahepatic disease, no ascites, <6.1 months from diagnosis to treatment
Number of subjects: 174
Study 38321316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based version of a feeding-focused childhood obesity prevention program
Number of subjects: 168
Study 38321316 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person attendance at nutrition education classes
Number of subjects: 168
Study 38321316 — intervention group
Group type: EXPERIMENTAL
Intervention: Online engagement with videos
Number of subjects: 168
Study 38321316 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic correlates of parent engagement
Number of subjects: 168
Study 38321316 — intervention group
Group type: EXPERIMENTAL
Intervention: Online engagement by ethnicity and acculturation
Number of subjects: 168
Study 38321316 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person attendance by acculturation
Number of subjects: 168
Study 38321372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular parkinsonism (VaP)
Number of subjects: 104
Study 38321372 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 104
Study 38321372 — intervention group
Group type: COMPARATOR
Intervention: Parkinson's disease (PD)
Number of subjects: 104
Study 38321454 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 80
Study 38321454 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole-loaded chitosan nanoparticles
Number of subjects: 80
Study 38321472 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 91
Study 38321472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 38321482 — intervention group
Group type: EXPERIMENTAL
Intervention: Malkia Klabu program
Number of subjects: 40
Study 38321507 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive blood pressure monitoring (C-NiBP)
Number of subjects: 1265
Study 38321507 — intervention group
Group type: COMPARATOR
Intervention: Intermittent non-invasive blood pressure monitoring (I-NiBP)
Number of subjects: 1265
Study 38321529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine administration
Number of subjects: 158
Study 38321529 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine administration in thiamine-deficient group
Number of subjects: 158
Study 38321567 — intervention group
Group type: EXPERIMENTAL
Intervention: SKY Schools intervention (social-emotional learning combined with Sudarshan Kriya Yoga)
Number of subjects: 49
Study 38321567 — intervention group
Group type: EXPERIMENTAL
Intervention: SKY Schools intervention
Number of subjects: 49
Study 38321576 — intervention group
Group type: EXPERIMENTAL
Intervention: Carers-ID online intervention (n = 60)
Number of subjects: 120
Study 38321576 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 60)
Number of subjects: 120
Study 38321617 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment overvaluation of shape/weight
Number of subjects: 129
Study 38321617 — intervention group
Group type: COMPARATOR
Intervention: Behaviorally-based treatments
Number of subjects: 129
Study 38321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (e.g., durvalumab, atezolizumab, nivolumab, pembrolizumab, tremelimumab, ipilimumab)
Number of subjects: 0
Study 38321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (e.g., tyrosine kinase inhibitors, monoclonal antibody immune checkpoint inhibitors)
Number of subjects: 0
Study 38321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines, cancer vaccines, adoptive T cell therapies, Natural killer cell therapies
Number of subjects: 0
Study 38322553 — intervention group
Group type: EXPERIMENTAL
Intervention: AllerPops prebiotic supplements
Number of subjects: 72
Study 38322707 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) and Model of Goal-Directed Behavior (MGB)
Number of subjects: 0
Study 38322707 — intervention group
Group type: EXPERIMENTAL
Intervention: Past efforts to control blood pressure
Number of subjects: 0
Study 38322862 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine infusion (0.75 mcg/ml) combined with sufentanil (1.5 mcg/ml) for 24 hours
Number of subjects: 80
Study 38322862 — intervention group
Group type: COMPARATOR
Intervention: Control group (sufentanil 1.5 mcg/ml alone)
Number of subjects: 80
Study 38322981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 25 mg 3 times/day if <80 kg and 50 mg 3 times/day if >80 kg for 14 days
Number of subjects: 99
Study 38322981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 38322981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 99
Study 38323147 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltimore Urban food Distribution (BUD) application
Number of subjects: 0
Study 38323173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosaprepitant (arm A)
Number of subjects: 108
Study 38323173 — intervention group
Group type: COMPARATOR
Intervention: Oral aprepitant (arm B)
Number of subjects: 108
Study 38323410 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum exosomal miRNA classifier (Cmi) comprising 3 miRNAs (miR-4265, 1208, 3127-5p)
Number of subjects: 743
Study 38323410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmi in post-ERCP pancreatitis cases
Number of subjects: 743
Study 38323410 — intervention group
Group type: COMPARATOR
Intervention: AP patients without POF (control group)
Number of subjects: 743
Study 38323417 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair using multi-branched off-the-shelf devices (Zenith t-branch, Cook Medical Inc.) in 88 patients, physician-modified endografts in 8 patients, patient-specific device or parallel grafts in 2 patients each.
Number of subjects: 100
Study 38323417 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair of rTAAA
Number of subjects: 100
Study 38323455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement (ABPM)
Number of subjects: 41
Study 38323455 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) velocity
Number of subjects: 41
Study 38323455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular assessment
Number of subjects: 41
Study 38323513 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized amlodipine dose titration (novel doses: 1, 2, 3, 4, 6, 7, 8, 9 mg; standard doses: 5 and 10 mg) over 14 weeks.
Number of subjects: 205
Study 38323608 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 156
Study 38323608 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A
Number of subjects: 156
Study 38323608 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 156
Study 38323608 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-4 (IL-4)
Number of subjects: 156
Study 38323608 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1α (IL-1α)
Number of subjects: 156
Study 38323656 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fragmented QRS complex (fQRS)
Number of subjects: 141
Study 38323656 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of inferior ST-T change
Number of subjects: 141
Study 38323656 — intervention group
Group type: EXPERIMENTAL
Intervention: Low- and intermediate-risk CTD-PAH with inferior ST-T change
Number of subjects: 141
Study 38323656 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curve analysis
Number of subjects: 141
Study 38323738 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 0
Study 38323855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 0
Study 38323855 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38323949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-based Creating Opportunities for Personal Empowerment program
Number of subjects: 299
Study 38323949 — intervention group
Group type: COMPARATOR
Intervention: Health promotion content
Number of subjects: 299
Study 38324012 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0
Study 38324012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviors
Number of subjects: 0
Study 38324085 — intervention group
Group type: EXPERIMENTAL
Intervention: Navarixin 30 mg plus pembrolizumab
Number of subjects: 105
Study 38324085 — intervention group
Group type: EXPERIMENTAL
Intervention: Navarixin 100 mg plus pembrolizumab
Number of subjects: 105
Study 38324085 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study 38324085 — intervention group
Group type: EXPERIMENTAL
Intervention: Navarixin 30 mg
Number of subjects: 105
Study 38324085 — intervention group
Group type: EXPERIMENTAL
Intervention: Navarixin 100 mg
Number of subjects: 105
Study 38324085 — intervention group
Group type: EXPERIMENTAL
Intervention: Navarixin plus pembrolizumab
Number of subjects: 105
Study 38324241 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-to-care strategy using a disease intervention specialist (DIS)
Number of subjects: 655
Study 38324241 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 655
Study 38324254 — intervention group
Group type: EXPERIMENTAL
Intervention: Influential patients in hemodialysis clinics
Number of subjects: 0
Study 38324254 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38324280 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker withdrawal
Number of subjects: 52
Study 38324314 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlantic diet intervention (educational sessions, cooking classes, written material, and foods characteristic of the Atlantic diet)
Number of subjects: 574
Study 38324314 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual lifestyle)
Number of subjects: 574
Study 38324313 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted group (including screening using biomarkers and MRI)
Number of subjects: 1500
Study 38324336 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCT-602
Number of subjects: 0
Study 38324336 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCT-602 + pacritinib
Number of subjects: 0
Study 38324336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide
Number of subjects: 0
Study 38324365 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION intervention (group sessions, physical activity self-monitoring-Fitbit, and text-based support for step goal setting)
Number of subjects: 224
Study 38324365 — intervention group
Group type: COMPARATOR
Intervention: Education control (an individual asthma education session and SMS text messages related to asthma education)
Number of subjects: 224
Study 38324365 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION intervention
Number of subjects: 224
Study 38324367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based treatment app (Spark)
Number of subjects: 168
Study 38324367 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control app (control)
Number of subjects: 168
Study 38324414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 336
Study 38324414 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 336
Study 38324415 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban, 5 mg or 2.5 mg, twice daily (n=507)
Number of subjects: 1015
Study 38324415 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 81 mg, once daily (n=508)
Number of subjects: 1015
Study 38324484 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-77242113 25 mg once daily
Number of subjects: 255
Study 38324484 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-77242113 25 mg twice daily
Number of subjects: 255
Study 38324484 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-77242113 50 mg once daily
Number of subjects: 255
Study 38324484 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-77242113 100 mg once daily
Number of subjects: 255
Study 38324484 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-77242113 100 mg twice daily
Number of subjects: 255
Study 38324484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 38324483 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg resmetirom
Number of subjects: 966
Study 38324483 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg resmetirom
Number of subjects: 966
Study 38324483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966
Study 38324512 — intervention group
Group type: EXPERIMENTAL
Intervention: Providence-type brace optimized by the semi-automatic algorithm leveraging a patient-specific FEM (Test)
Number of subjects: 58
Study 38324512 — intervention group
Group type: COMPARATOR
Intervention: Conventional Providence-type brace (Control)
Number of subjects: 58